Syddansk Universitet
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Jul 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Glycosylated Yghj Polypeptides from Enterotoxigenic Escherichia Coli (ETEC) (US 11,655,274) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Assembly for assessing drug permeability with adjustable biomimetic properties (US 10,473,574) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Auger electron therapy for glioblastoma (US 10,583,210) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Glycosylated Yghj Polypeptides from Enterotoxigenic Escherichia Coli (ETEC) (US 10,647,749) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,915,008 | Methods for isolation and analysis of sialylated and phosphorylated peptides In force · From the USPTO record | In force | From the USPTO record | |
| US 9,015,659 | Method, Computer Program Product, and System for Non-Blocking Dynamic Update of Statically Typed Class-Based Object-Oriented Software In force · Low confidence | In force | Low confidence | |
| US 9,476,888 | Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination In force · From the USPTO record | In force | From the USPTO record | |
| US 9,988,442 | MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,266,828 | Ras Exon 2 Skipping for Cancer Treatment In force · High confidence | In force | High confidence | |
| US 10,583,210 | Auger electron therapy for glioblastoma In force · From the USPTO record | In force | From the USPTO record | |
| US 10,473,574 | Assembly for assessing drug permeability with adjustable biomimetic properties In force · From the USPTO record | In force | From the USPTO record | |
| US 10,647,749 | Glycosylated Yghj Polypeptides from Enterotoxigenic Escherichia Coli (ETEC) In force · High confidence | In force | High confidence | |
| US 11,655,274 | Glycosylated Yghj Polypeptides from Enterotoxigenic Escherichia Coli (ETEC) In force · High confidence | In force | High confidence | |
| US 11,457,799 | Dual-mode endoscopic capsule with image processing capabilities In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 20: 16 patents in force now held by others · 17 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 3 abandoned · 22 no status recorded